Patent intelligence · US
US 10286036
Protocol for treatment of lupus nephritis
Protocol for treatment of lupus nephritis
Patent details — US 10286036
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 14, 2019
- Expiration
- May 9, 2039
- Applicant
- AURINIA PHARMACEUTICALS INC.
- Claims
- 13
- CPC classes
- A61K, A61K31/365, A61K31/573, A61K38/13
Quick answer
US 10286036 (Protocol for treatment of lupus nephritis) is held by AURINIA PHARMACEUTICALS INC.. Status: granted. Granted May 14, 2019. Expires May 9, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AURINIA PHARMACEUTICALS INC.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/365, A61K31/573, A61K38/13, A61P, A61P13/12
More from AURINIA PHARMACEUTICALS INC.
Related pharmaceutical patents in our USPTO index.
-
US 11622991
Protocol for treatment of lupus nephritis
granted -
US 10973871
Ophthalmic compositions
granted -
US 10472394
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted -
US 10265375
Ophthalmic compositions
granted -
US 9765119
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted -
US 9017725
Topical drug delivery systems for ophthalmic use
granted
Frequently asked questions
What is US patent 10286036?
US 10286036 (Protocol for treatment of lupus nephritis) is held by AURINIA PHARMACEUTICALS INC.. Status: granted. Granted May 14, 2019. Expires May 9, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10286036?
AURINIA PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 10286036 expire?
Our index shows an expiration date of May 9, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.